ACSL3 emerges as a biomarker for clinical prognosis in NSCLC for the identification of patients that would benefit from anticancer properties of statin treatments that are safe, well‐tolerated, and low cost. This evidence concerns the gene ACSL3 and non-small cell lung carcinoma.